* Study shows improved blood pumping
* Study shows low mortality rate
Sept 23 (Reuters) - Abiomed Inc said data from a registry of patients using its heart pump showed low mortality rates and continued improvement in blood pumping.
The heart-device maker said patients treated with Impella 2.5 showed improvement in left ventricle ejection fraction (LVEF) -- a measure of how well the heart pumps out blood -- in both settings of treatment.
Patients who used the device to prevent any heart-related adverse event showed a 17 percent improvement in LVEF and a 3.9 percent mortality rate.
Data from patients treated on an emergent basis showed a 19 percent improvement in LVEF at the time of being discharged and a 59 percent reduction in mortality.
Abiomed's results from the registry USpella include data from 352 patients.
Shares of the Danvers, Massachusetts-based company have risen 10 percent in value since the company presented positive data from the registry in September last year. They were up 1 cent at $10.44 Thursday morning on Nasdaq.
(Reporting by Vidya L Nathan in Bangalore; Editing by Anne Pallivathuckal) Keywords: ABIOMED/ (vidya.loganathan@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800; Reuters Messaging: vidya.loganathan.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Study shows low mortality rate
Sept 23 (Reuters) - Abiomed Inc said data from a registry of patients using its heart pump showed low mortality rates and continued improvement in blood pumping.
The heart-device maker said patients treated with Impella 2.5 showed improvement in left ventricle ejection fraction (LVEF) -- a measure of how well the heart pumps out blood -- in both settings of treatment.
Patients who used the device to prevent any heart-related adverse event showed a 17 percent improvement in LVEF and a 3.9 percent mortality rate.
Data from patients treated on an emergent basis showed a 19 percent improvement in LVEF at the time of being discharged and a 59 percent reduction in mortality.
Abiomed's results from the registry USpella include data from 352 patients.
Shares of the Danvers, Massachusetts-based company have risen 10 percent in value since the company presented positive data from the registry in September last year. They were up 1 cent at $10.44 Thursday morning on Nasdaq.
(Reporting by Vidya L Nathan in Bangalore; Editing by Anne Pallivathuckal) Keywords: ABIOMED/ (vidya.loganathan@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800; Reuters Messaging: vidya.loganathan.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.